๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

429. - An open-label study of fluvoxamine in body dysmorphic disorder

โœ Scribed by K.A. Phillips; S.L. McElroy

Book ID
118858501
Publisher
Elsevier Science
Year
1996
Tongue
English
Weight
138 KB
Volume
39
Category
Article
ISSN
0006-3223

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Pilot open-label study of nefazodone in
Pilot open-label study of nefazodone in panic disorder
โœ Alexander Bystritsky; Richard Rosen; Rita Suri; Tanya Vapnik ๐Ÿ“‚ Article ๐Ÿ“… 1999 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 56 KB ๐Ÿ‘ 2 views

Ten patients meeting DSM-IV criteria for non-comorbid panic disorder or panic disorder with agoraphobia were treated in a 12-week open-label, flexible dosage trial of nefazodone. Dosages ranged from 50 to 400 mg per day. Clinical assessment utilized several recently developed scales of panic disorde

Fluvoxamine is ineffective in the treatm
Fluvoxamine is ineffective in the treatment of enuresis in children and adolescents: an open-label pilot study
โœ Paz Toren; Sofia Eldar; Nathaniel Laor; Leo Wolmer; Eliahu Samuel; Ronit Weizman ๐Ÿ“‚ Article ๐Ÿ“… 2001 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 62 KB ๐Ÿ‘ 1 views

Tricyclic antidepressants possess established antienuretic properties. The selective serotonin reuptake inhibitors (SSRIs) have similar antidepressant properties to the tricyclic antidepressants and a safer side effect profile. The aim of the present study was to evaluate the antienuretic efficacy o